Xing Chen1, Collin E M Brathwaite2,3,4, Alexander Barkan2, Keneth Hall2, Gloria Chu2, Patricia Cherasard2, Shan Wang1, David P Nicolau3,4, Shahidul Islam5, Burke A Cunha6,7. 1. Department Pharmacy, Winthrop-University Hospital, Mineola, NY, USA. 2. Department of Surgery, Winthrop-University Hospital, Mineola, NY, USA. 3. State University of New York, School of Medicine, Stony Brook, NY, USA. 4. Center of Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA. 5. Department of Biostatistics, Winthrop-University Hospital, Mineola, NY, USA. 6. State University of New York, School of Medicine, Stony Brook, NY, USA. bacunha@winthrop.org. 7. Infectious Disease Division, Winthrop-University Hospital, Mineola, NY, 11501, USA. bacunha@winthrop.org.
Abstract
PURPOSE: The goal of this pharmacokinetic (PK) study was to evaluate whether a single 2-g prophylactic dose of cefazolin given (IV) bolus provides effective protective cefazolin levels for prophylaxis against methicillin-sensitive S. aureus (MSSA), the primary skin pathogen in bariatric surgery. MATERIALS AND METHODS: Thirty-seven patients having gastric bypass or sleeve gastrectomy received cefazolin 2-g preoperative prophylaxis. Serum, subcutaneous adipose tissue, and deep peri-gastric adipose tissue specimens were collected at incision and before skin closure. Cefazolin concentrations in serum and adipose tissue were determined by high-performance liquid chromatography. RESULTS: Penetration of cefazolin, a water soluble antibiotic, into adipose tissue was only 6-8 % of simultaneous serum levels. However, cefazolin tissue concentrations in all adipose tissue specimens, exceeded mean MIC for MSSA. CONCLUSIONS: Prophylactic cefazolin, given as a single 2 g (IV bolus 3-5 min before skin incision) was more than adequate in providing protective cefazolin levels for the duration of bariatric surgery. Cefazolin 2 g (IV dose bolus given just before skin incision) achieves protective adipose tissue levels (> MIC of MSSA) for the duration (usually < 4 h) of bariatric surgical procedures. In this study, cefazolin 2 g (IV bolus) provided protective adipose tissue levels for 4.8 h. Since cefazolin is a water soluble antibiotic (V d = 0.2 L/Kg), penetration into adipose tissue is not V d not dose-dependent. Extremely high-dosed cefazolin, i.e., 3 or 4 g is excessive and unnecessary for bariatric surgery prophylaxis. A single cefazolin 2 g preoperative dose also eliminates the need for intraoperative redosing at 4 h.
PURPOSE: The goal of this pharmacokinetic (PK) study was to evaluate whether a single 2-g prophylactic dose of cefazolin given (IV) bolus provides effective protective cefazolin levels for prophylaxis against methicillin-sensitive S. aureus (MSSA), the primary skin pathogen in bariatric surgery. MATERIALS AND METHODS: Thirty-seven patients having gastric bypass or sleeve gastrectomy received cefazolin 2-g preoperative prophylaxis. Serum, subcutaneous adipose tissue, and deep peri-gastric adipose tissue specimens were collected at incision and before skin closure. Cefazolin concentrations in serum and adipose tissue were determined by high-performance liquid chromatography. RESULTS: Penetration of cefazolin, a water soluble antibiotic, into adipose tissue was only 6-8 % of simultaneous serum levels. However, cefazolin tissue concentrations in all adipose tissue specimens, exceeded mean MIC for MSSA. CONCLUSIONS: Prophylactic cefazolin, given as a single 2 g (IV bolus 3-5 min before skin incision) was more than adequate in providing protective cefazolin levels for the duration of bariatric surgery. Cefazolin 2 g (IV dose bolus given just before skin incision) achieves protective adipose tissue levels (> MIC of MSSA) for the duration (usually < 4 h) of bariatric surgical procedures. In this study, cefazolin 2 g (IV bolus) provided protective adipose tissue levels for 4.8 h. Since cefazolin is a water soluble antibiotic (V d = 0.2 L/Kg), penetration into adipose tissue is not V d not dose-dependent. Extremely high-dosed cefazolin, i.e., 3 or 4 g is excessive and unnecessary for bariatric surgery prophylaxis. A single cefazolin 2 g preoperative dose also eliminates the need for intraoperative redosing at 4 h.
Authors: Vanessa P Ho; David P Nicolau; Gregory F Dakin; Alfons Pomp; Barrie S Rich; Christopher W Towe; Philip S Barie Journal: Surg Infect (Larchmt) Date: 2012-02-08 Impact factor: 2.150
Authors: Simone van Kralingen; Margot Taks; Jeroen Diepstraten; Ewoudt M van de Garde; Eric P van Dongen; Marinus J Wiezer; Bert van Ramshorst; Bart Vlaminckx; Vera H Deneer; Catherijne A Knibbe Journal: Eur J Clin Pharmacol Date: 2011-04-16 Impact factor: 2.953
Authors: Dale W Bratzler; E Patchen Dellinger; Keith M Olsen; Trish M Perl; Paul G Auwaerter; Maureen K Bolon; Douglas N Fish; Lena M Napolitano; Robert G Sawyer; Douglas Slain; James P Steinberg; Robert A Weinstein Journal: Am J Health Syst Pharm Date: 2013-02-01 Impact factor: 2.637
Authors: Jerry T Dang; Vivian G Szeto; Ahmad Elnahas; James Ellsmere; Allan Okrainec; Amy Neville; Samaad Malik; Ekua Yorke; Dennis Hong; Laurent Biertho; Timothy Jackson; Shahzeer Karmali Journal: Surg Endosc Date: 2019-06-17 Impact factor: 4.584
Authors: Rochelle L Ryan; Dwane Jackson; George Hopkins; Victoria Eley; Rebecca Christensen; Andre A J Van Zundert; Steven C Wallis; Jeffrey Lipman; Suzanne L Parker; Jason A Roberts Journal: Antimicrob Agents Chemother Date: 2022-06-28 Impact factor: 5.938
Authors: Hanadi H Alrammaal; Khaled Abduljalil; Victoria Hodgetts Morton; R Katie Morris; John F Marriott; Hsu P Chong; Hannah K Batchelor Journal: Pharmaceutics Date: 2022-05-30 Impact factor: 6.525
Authors: Eduardo Celia Palma; Nelson Guardiola Meinhardt; Airton Tetelbom Stein; Isabela Heineck; Maria Isabel Fischer; BibianaVerlindo de Araújo; Teresa Dalla Costa Journal: Pharm Res Date: 2018-04-11 Impact factor: 4.200
Authors: Zahid Hussain; Colin Curtain; Corinne Mirkazemi; Karl Gadd; Gregory M Peterson; Syed Tabish R Zaidi Journal: Obes Surg Date: 2019-01 Impact factor: 4.129
Authors: Sonia Bianchini; Erika Rigotti; Sara Monaco; Laura Nicoletti; Cinzia Auriti; Elio Castagnola; Giorgio Conti; Luisa Galli; Mario Giuffrè; Stefania La Grutta; Laura Lancella; Andrea Lo Vecchio; Giuseppe Maglietta; Nicola Petrosillo; Carlo Pietrasanta; Nicola Principi; Simonetta Tesoro; Elisabetta Venturini; Giorgio Piacentini; Mario Lima; Annamaria Staiano; Susanna Esposito Journal: Antibiotics (Basel) Date: 2022-02-21